(2R,4R)-Methyl-2-tert-butyl-1,3-thiazolidine-3-formyl-4-carboxylate (18)
the resulting crude was purified by flash chromatography on silica gel (eluted by 30–50% ethyl acetate in hexane). The collected fractions were evaporated and recrystallized from diethyl ether–hexanes (1:1, v/v) to afford N-formyl thazolidine 18 (300 g, 90% yield, 97% HPLC purity) as colorless crystals.
1H NMR (400 MHz, CDCl3, mixture of conformers (7:1), major): δ 8.35 (s, 1H), 4.89 (t, J = 8.0 Hz, 1H), 4.74 (s, 1H), 3.77 (s, 3H), 3.34–3.24 (m, 2H), 1.03 (s, 9H) ppm.
13C NMR (100 MHz, CDCl3, mixture of conformers (7:1), major): δ 170.1, 162.8, 75.3, 61.6, 52.8, 38.7, 33.0, 26.5 ppm. HRMS (ESI) m/z calcd for C10H17NO3S (M+H)+ 232.1002, found 232.1001.
Process Development and Scale-up Total Synthesis of Largazole, a Potent Class I Histone Deacetylase Inhibitor
†Department of Medicinal Chemistry and ‡Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, Florida 32610, United States
§ Oceanyx Pharmaceuticals, Inc., Sid Martin Biotechnology Incubator, 12085 Research Drive, Alachua, Florida 32615, United States
Org. Process Res. Dev., Article ASAP
DOI: 10.1021/acs.oprd.7b00352
Abstract
Herein we describe the research and development of the process for the scale-up total synthesis of largazole, a potent class I selective histone deacetylase (HDAC) inhibitor, a potential anticancer agent and also useful for the treatment of other disorders where transcriptional reprogramming might be beneficial. The synthetic route and conditions for each fragment and final product were modified and optimized to make them suitable for larger-scale synthesis. With the process we developed, hundreds of grams of each fragment and decagrams of final product largazole were synthesized in good to excellent yields. The final target largazole was obtained in 21% overall yield over eight steps based on the longest sequence with over 95% HPLC purity.
//////////
No comments:
Post a Comment